Overview A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer Status: Not yet recruiting Trial end date: 2023-06-30 Target enrollment: Participant gender: Summary This is a study to evaluate the efficacy and safety of TQB2450 injection in the treatment of PD-L1 positive recurrent or metastatic cervical cancer. Phase: Phase 2 Details Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.